Trial
NCT05580588
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Shanghai Pharma Biotherapeutics USA Inc.
Collaborators
—
Condition
Liposarcoma, Dedifferentiated
Intervention
SPH4336
Why stopped
Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less than anticipated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-13